Earnings Release • Mar 1, 2012
Earnings Release
Open in ViewerOpens in native device viewer
Leiden, The Netherlands, March 1, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today published its preliminary (unaudited) financial results for the year ended December 31, 2011.
*This excludes approximately €1.1 million to be received from Sobi for Q4 2011 – Q2 2012 supplies and the €8.0 million proceeds following the late December 2011 issuance of convertible bonds.
(A conference call for analysts and press will be held at 10:00 CET, details provided below)
Chief Executive Officer of Pharming, Sijmen de Vries, commented: "During the year we have focused on improving our operational cash burn and have continued to seek new business development opportunities in new geographies and new projects. The ability to access capital is a key risk to our business and in 2011, despite difficult market conditions, we were able to identify new sources of funding, enabling us to bridge the financing gap between the Refusal To File letter that we received early in 2011 from the US FDA for Rhucin® and the anticipated read-out of our ongoing clinical trial, Study 1310, which continued with changes requested by the FDA through a SPA agreement. All in all, 2011 proved to be a challenging year, but despite that we were able to strengthen the foundations for future growth and we look forward to building on this in 2012."
The most important activity in the near term continues to be the ongoing pivotal clinical trial (Study 1310) which is required for US regulatory approval for Rhucin®. This study remains on track and we anticipate readout by Q3 2012. If successful we anticipate submitting a BLA approximately three months thereafter. These events are associated with large milestones payments which will have a significant impact on the company's future growth. On successful achievement of the primary endpoint of the Phase III clinical study, the Company is eligible to receive a US\$10.0 million milestone payment from Santarus and a further US\$5.0 million at the acceptance of the BLA by the FDA.
We remain focused on supporting our commercialisation partners in facilitating the rollout of Ruconest® across the licensed territories and look forward to continued progress over the coming quarters. Discussions are on-going with several parties regarding the potential commercialisation of Ruconest® in other territories of the world, such as South America, other South-East Asian countries and Japan. Such deals are important in increasing the geographical coverage of our Hereditary angioedema (HAE) franchise. In early 2012 we signed our first distribution partner in South-East Asia (Transmedic Pte) and we hope to be able to update you on additional deals over the coming quarters.
Following the validation of our transgenic platform with the EU approval of Ruconest®, we have received multiple requests regarding the potential licensing of the platform, and/ or co-development collaborations to produce complex proteins. These discussions are at an early stage and focus on significant indications which already have protein therapeutics on the market. The attractiveness of our platform appears to be its scalability, low upfront capital investments in manufacturing and its flexibility associated with manufacturing costs. We do envisage moving forward with new platform projects with partners and are currently exploring such possibilities. In 2011 we took the important initial step of signing an agreement with Renova Life to produce rabbits for the production of recombinant Factor VIII.
In 2011 we prioritized our pipeline and decided to out-license our non-core programmes. Discussions are ongoing with potential partners for lactoferrin and fibrinogen.
Revenues and other income from continuing operations increased to €3.2 million (2010: €1.1 million), largely reflecting a revenue increase from €0.6 million in 2010 to €3.0 million in 2011. The revenue increase includes the full year effect of license fee revenues of €1.9 million (2010: €0.5 million) and product supplies to Sobi of €1.1 million (2010: €0.1 million). In 2011 the Company incurred €1.7 million inventory impairments related to production issues related to a one-off event. The Company is investigating various possibilities to fully recover these costs.
Operating costs from continuing operations excluding cost of sales decreased to €19.9 million (2010: €22.2 million). The reduction is mainly a result of decreasing R&D costs from €18.3 million in 2010 to €13.8 million in 2011. This reflects 2010 impairment charges on R&D inventories, the continued prioritization of R&D expenditure towards Study 1310, minimal expenditure on other projects and an increased focus on cost containment in our US business.
Net profit from financial income and expenses in 2011 was €0.7 million compared to a net loss in 2010 of €16.5 million. These items in 2010 were largely driven by the interest charges and settlement charges of various debts incurred in 2010 and earlier years.
Net loss from continuing operations decreased to €17.8 million (2010: €37.7 million). The net profit from discontinued operations in 2011 of €0.6 million compared to a net loss from discontinued operations in 2010 of €18.7 million. The effects of discontinued operations relate to the liquidation of the DNage business in early 2011, with 2010 losses largely driven by €20.7 million (non-cash) impairment charges on goodwill and intangible assets. The overall net loss significantly decreased from €56.4 million in 2010 to €17.2 million in 2011.
Throughout 2011, the company raised €3.2 million of new funds through a private placement and signed a convertible bond financing (€8.0 million gross proceeds) subject to shareholder approval in 2012 (which has been obtained through an Extraordinary General Meeting of Shareholders (EGM) held on February 3, 2012).
Year-end cash and cash equivalents (including restricted cash) amounted to €5.1 million. This amount excludes the cash proceeds from the convertible bond (€8.0 million gross) and €1.1 million outstanding as part of the Sobi extension agreement, the former amount having been received in early 2012 and the latter partially received early 2012 and partially due by end Q2 2012.
Net cash flows used in operating activities increased from €3.2 million in 2010 to €16.9 million in 2011. However, cash inflows in 2010 were augmented by one off upfront and milestone payments paid by Santarus and Sobi of €19.7 million and in 2010 payments with respect to the discontinued DNage business of €2.9 million (2011: nil). Thus, on a comparable basis, operating cash outflows decreased by €3.1 million in 2011 compared to 2010.
In late 2011 the Company announced that it had entered negative equity. The negative equity position has in itself no immediate impact on the execution of the Pharming's business plan, nor does it imply that the Company is legally required to issue new share capital. An EGM was held on February 3, 2012 and the authorised share capital increased to 805 million shares. Pharming is continuously reviewing its financial and liquidity position and has various options to improve its equity standing under International Financial Reporting Standards (IFRS). Most notably, the Company highlights that the negative equity position was mainly caused by its inability to recognize the €19.7 million upfront payments and milestones received from Sobi and Santarus as equity and that it expects to receive two development milestones associated with the successful readout of Study 1310 (US\$10.0 million) and acceptance of the BLA filing by the FDA (US\$5.0 million). Under IFRS, Pharming expects to be able to recognize these milestones immediately and thus augment the equity position.
Pharming will hold its Annual General Meeting of Shareholders on May 14, 2012.
Today, Chief Executive Officer, Sijmen de Vries and Chief Financial Officer, Karl Keegan will present the preliminary full year 2011 results in a conference call for analysts at 10:00 am CET. To participate, please call one of the following numbers 10 minutes prior to the call:
Analyst call (Confirmation Code: 4520748) Participant Telephone Numbers: From the Netherlands: 08002658611 (toll-free) or 31 (0) 45 6316902 From the UK: 0800-358-0886 (toll-free) or 44-207-153-2027
To view the presentation live during the call, please follow the below link: http://event.on24.com/r.htm?e=411566&s=1&k=34F366E0488A4DB5E3906183B47930C8
Following a brief presentation of the results, the lines will be opened for a question and answer session. An audio cast of the conference calls will be available on Pharming's website shortly thereafter.
Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® (RHUCIN® in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU
by Swedish Orphan Biovitrum (OMX: SOBI). RHUCIN® is partnered with Santarus, Inc (NASDAQ: SNTS) in North America where the drug is undergoing Phase III clinical development. The product is also being evaluated for additional indications in the areas of transplantation and reperfusion injury. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products. Recently a new project, using the validated transgenic rabbit platform, aimed at the development of recombinant Factor VIII for the treatment of Haemophilia A was initiated was initiated by partner, Renova Life, Inc. Additional information is available on the Pharming website, www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
Sijmen de Vries, CEO: T: +31 524 7400 Karl Keegan, CFO: T: +31 524 7400
FTI Consulting Julia Phillips/ John Dineen, T: +44 (0)207 269 7193
(amounts in €'000) (unaudited)
| December 31, 2011 |
December 31, 2010 |
|
|---|---|---|
| Intangible assets | 987 | 1,163 |
| Property, plant and equipment | 9,567 | 6,702 |
| Restricted cash | 979 | 176 |
| Non-current assets | 11,533 | 8,041 |
| Inventories | 6,580 | 9,013 |
| Trade and other receivables | 2,495 | 9,932 |
| Restricted cash | 309 | - |
| Cash and cash equivalents | 3,777 | 10,302 |
| Current assets | 13,161 | 29,247 |
| Total assets | 24,694 | 37,288 |
| Share capital | 20,405 | 17,450 |
| Share premium | 224,495 | 219,220 |
| Other reserves | (246,088) | (225,806) |
| Shareholders' equity | (1,188) | 10,864 |
| Non-controlling interest | - | (764) |
| Total equity | (1,188) | 10,100 |
| Deferred license fees income | 15,431 | 17,342 |
| Finance lease liabilities | 2,215 | 32 |
| Other liabilities | 101 | 130 |
| Non-current liabilities | 17,747 | 17,504 |
| Deferred license fees income | 1,936 | 1,936 |
| Derivative financial liabilities | 1,171 | 573 |
| Trade and other payables | 3,810 | 7,130 |
| Finance lease liabilities | 1,218 | 45 |
| Current liabilities | 8,135 | 9,684 |
| Total equity and liabilities | 24,694 | 37,288 |
| December 31, 2011 |
December 31, 2010 |
|
|---|---|---|
| Continuing operations: Revenues Cost of revenues Inventory impairments Gross profit /(loss) |
2,999 (1,814) (1,716) (531) |
573 (91) - 482 |
| Income from grants Other income |
196 196 |
515 515 |
| Research and development General and administrative Impairment charges Share-based compensation Costs |
(13,830) (3,262) (35) (1,039) (18,166) |
(18,307) (3,209) - (636) (22,152) |
| Loss from operating activities | (18,501) | (21,155) |
| Financial income Financial expenses Financial income and expenses |
1,026 (368) 658 |
- (16,512) (16,512) |
| Net loss from continuing operations | (17,843) | (37,667) |
| Net profit/(loss) from discontinued operations | 643 | (18,700) |
| Net loss | (17,200) | (56,367) |
| Attributable to: Net loss from continuing operations Net profit/(loss) from discontinued operations Owners of the parent |
(17,843) 739 (17,104) |
(37,667) (12,548) (50,215) |
| Net loss from continuing operations Net profit/(loss) from discontinued operations Non-controlling interest |
- (96) (96) |
- (6,152) (6,152) |
| Share information: Basic and diluted net loss per share (€) Weighted average shares outstanding |
(0.04) 470,223,995 |
(0.19) 266,313,183 |
| December 31, 2011 |
December 31, 2010 |
|
|---|---|---|
| Receipts from license partners | 814 | 20,355 |
| Receipts of Value Added Tax | 1,162 | 1,519 |
| Interest received | 1 | 78 |
| Receipts of grants | 384 | 367 |
| Other receipts | 240 | 414 |
| Payments of third party fees and expenses, including Value Added Tax | (12,663) | (18,583) |
| Net compensation paid to board members and employees | (3,790) | (3,817) |
| Payments of pension premiums, payroll taxes and social securities, net | ||
| of grants settled | (3,078) | (3,002) |
| Interest paid | (100) | |
| Other payments | - | (389) |
| Net cash flows used in operating activities | (16,930) | (3,158) |
| Purchase of property, plant and equipment | (1,058) | (909) |
| Deconsolidation of DNage | (40) | - |
| Net cash flows used in investing activities | (1,098) | (909) |
| Net proceeds of equity and warrants issued | 13,198 | 18,240 |
| Gross proceeds convertible bonds issued | - | 7,500 |
| Receipt from financial lease transaction | 618 | - |
| Payments of transaction fees and expenses | (369) | (1,146) |
| Payments convertible bonds | - | (10,900) |
| Payments of nominal interest convertible bonds | - | (750) |
| Payments of financial leases | (790) | (49) |
| Net cash flows from financing activities | 12,657 | 12,895 |
| Net increase/(decrease) cash and cash equivalents | (5,371) | 8,828 |
| Exchange rate effects on cash and cash equivalents | (42) | (688) |
| Net cash and cash equivalents at January 1 | 10,478 | 2,338 |
| Net cash and cash equivalents at December 31 | 5,065 | 10,478 |
| Liquidity information | ||
| Restricted cash (non-current) | 979 | 176 |
| Restricted cash (current) | 309 | - |
| Cash and cash equivalents | 3,777 | 10,302 |
| Net cash and cash equivalents at December 31 | 5,065 | 10,478 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.